In the latest Qnexa news, some exciting results have been published in the Journal of the American Medical Association which Vivus, Qnexa’s creators, hope will win them the approval of the FDA (Food and Drug Administration). It was the first population based study carried out on the risk of birth defects from anti-epileptic treatment, topiramate, a key ingredient in this weight loss treatment hopeful.
This was a large scale study based on data collected between 1996 and 2008 which looked at 838,000 births in Denmark where mothers had taken topiramate and it was discovered that topiramate did not increase the occurrence of birth defects to any significant level.
Presently, Vivus is carrying out a trial based on recent but existing data which will study the children of mothers who took topiramate. Vivus recently requested that their drug be approved for those who cannot have children but if similar results are collected in this present study, Qnexa might be approved for all obese and overweight men and women.